Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Powershares Db Multi-Sector Commodi Powershares Db Oil Fund
DBO
5
SPDR S&P Oil & Gas Exploration & Production ETF
XOP
US Stock MarketDetailed Quotes
Ocular Therapeutix (OCUL)
- 8.250
- -0.550-6.25%
Close Jun 5 16:00 ET
- 8.300
- +0.050+0.61%
Post 19:07 ET
1.81BMarket Cap-5.73P/E (TTM)
8.880High8.165Low1.35MVolume8.825Open8.800Prev Close11.34MTurnover0.73%Turnover RatioLossP/E (Static)218.96MShares16.44052wk High3.11P/B1.52BFloat Cap6.23052wk Low--Dividend TTM184.63MShs Float44.190Historical High--Div Yield TTM8.13%Range %1.995Historical Low8.409Avg Price1Lot Size
Ocular Therapeutix (OCUL) News
William Blair Updates Its Conviction List
Belite Bio: Buy Rating Reiterated as Tinlarebant Advances Toward 1Q27 Stargardt NDA Approval With Unchanged $200 Price Target
Selling Ocular Therapeutix Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
H.C. Wainwright Remains a Buy on Harrow Health (HROW)
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Express News | Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ocular Therapeutix Price Target Maintained With a $18.00/Share by Needham
Chardan Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21
Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says
RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target
A Quick Look at Today's Ratings for Ocular Therapeutix(OCUL.US), With a Forecast Between $18 to $30
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks
Ocular Therapeutix Outlines SOL-R Top Line Data in Q1 2027 While Advancing AXPAXLI NDA Plan
Ocular Therapeutix Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results.
Axpaxli's Strong Phase III Data and Favorable FDA Path Support Buy Rating and Unchanged $20 Price Target
Analyst Reiterates Buy on Axpaxli Ahead of NDA Filing and Key SOL-R/SOL-X Data Catalysts
Ocular Therapeutix | 8-K: Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix | 10-Q: Q1 2026 Earnings Report
Ocular Therapeutix's Q1 Net Loss Widens, Revenue Rises
Earnings Scheduled For May 5, 2026
Market Insights
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
On June 3, Eastern Time, the U.S. House of Representatives passed a resolution limiting Trump's authority to use military force against Iran
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm